Summary of baseline information
| ARIA-E Cases | Non-ARIA Cases | Overall | |
|---|---|---|---|
| No. of subjects | 10 | 10 | 20 |
| Age (mean) (±SD) | 69.4 (9.5) | 69.2 (8.4) | 69.3 (8.7) |
| MMSE (mean) (±SD) | 20.2 (3.9) | 21.2 (2.7) | 20.7 (3.3) |
| ADAS-cog11 (mean) (SD) | 22.0 (1.27) | 21.8 (5.6) | 21.9 (9.6) |
| DAD (mean) (±SD) | 81.9 (18.8) | 85.2 (11.2) | 83.5 (15.2) |
| Female (No.) (%) | 7 (70.0%) | 4 (40.0%) | 5 (55.0%) |
| ApoE ϵ4 status | |||
| ApoE ϵ4 noncarrier (No.) (%) | 3 (30.0%) | 1 (10.0%) | 4 (20.0%) |
| ApoE ϵ4 (No.) (%) | 3 (30.0%) | 5 (50.0%) | 8 (40.0%) |
| ApoE ϵ4 homozygote (No.) (%) | 4 (40.0%) | 4 (40.0%) | 8 (40.0%) |
| Bapineuzumab | |||
| 0.15 mg/kg (No.) (%) | 1 (10.0%) | 1 (10.0%) | 2 (10.0%) |
| 0.5 mg/kg (No.) (%) | 1 (10.0%) | 2 (20.0%) | 3 (15.0%) |
| 1.0 mg/kg (No.) (%) | 2 (20.0%) | 3 (30.0%) | 5 (25.0%) |
| 2.0 mg/kg (No.) (%) | 6 (60.0%) | 4 (40.0%) | 10 (50.0%) |
Note:—DAD indicates Disability Assessment for Dementia; ADAS-cog11, Alzheimer's Disease Assessment Scale-cognition (11 items); MMSE, Mini-Mental State Examination.